# Invesco DB Precious Metals Fund: financial statements, quarterly

DBP · NYSE · CIK 1383057 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dbp.md) · [Financials](/companies/dbp/financials.md) · [Filings](/companies/dbp/filings.md) · [Insiders](/companies/dbp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dbp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $m | [1.8](/filings/0000950170-24-122598.md) | [1.7 d](/filings/0001193125-26-083554.md) | [1.6](/filings/0000950170-25-067198.md) | [1.7](/filings/0000950170-25-105195.md) | [1.9](/filings/0001193125-25-270317.md) | [1.8 d](/filings/0001193125-26-083554.md) | [1.4](/filings/0001193125-26-209730.md) | [1.6](/filings/0001193125-26-338717.md) | [1.7](/filings/0001193125-25-270317.md) | [1.8 d](/filings/0001193125-26-083554.md) | [2.0](/filings/0001193125-26-209730.md) | [2.2](/filings/0001193125-26-338717.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-122598.md) | [0.0 d](/filings/0000950170-25-027250.md) | [0.0](/filings/0000950170-25-067198.md) | [0.0](/filings/0000950170-25-105195.md) | [0.0](/filings/0001193125-25-270317.md) | [0.0 d](/filings/0000950170-25-027250.md) | [0.0](/filings/0000950170-25-067198.md) | [0.0](/filings/0000950170-25-105195.md) | [0.0](/filings/0001193125-25-270317.md) | not reported | not reported | not reported |
| Net income | $m | [(5.3)](/filings/0000950170-24-122598.md) | [13.2 d](/filings/0001193125-26-083554.md) | [9.1](/filings/0000950170-25-067198.md) | [10.9](/filings/0000950170-25-105195.md) | [18.0](/filings/0001193125-25-270317.md) | [(1.7) d](/filings/0001193125-26-083554.md) | [27.3](/filings/0001193125-26-209730.md) | [8.8](/filings/0001193125-26-338717.md) | [34.4](/filings/0001193125-25-270317.md) | [42.0 d](/filings/0001193125-26-083554.md) | [15.2](/filings/0001193125-26-209730.md) | [(42.3)](/filings/0001193125-26-338717.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [137](/filings/0000950170-23-060458.md) | [149](/filings/0000950170-25-027250.md) | [147](/filings/0000950170-24-054976.md) | [155](/filings/0000950170-24-092095.md) | [180](/filings/0000950170-24-122598.md) | [156](/filings/0001193125-26-083554.md) | [203](/filings/0000950170-25-067198.md) | [187](/filings/0000950170-25-105195.md) | [222](/filings/0001193125-25-270317.md) | [258](/filings/0001193125-26-338717.md) | [279](/filings/0001193125-26-209730.md) | [241](/filings/0001193125-26-338717.md) |
| Total liabilities | $m | [1.2](/filings/0000950170-23-060458.md) | [1.1](/filings/0000950170-25-027250.md) | [0.1](/filings/0000950170-24-054976.md) | [0.1](/filings/0000950170-24-092095.md) | [1.0](/filings/0000950170-24-122598.md) | [1.1](/filings/0001193125-26-083554.md) | [0.1](/filings/0000950170-25-067198.md) | [0.3](/filings/0000950170-25-105195.md) | [0.1](/filings/0001193125-25-270317.md) | [0.2](/filings/0001193125-26-338717.md) | [0.2](/filings/0001193125-26-209730.md) | [0.1](/filings/0001193125-26-338717.md) |
| Shareholders' equity | $m | [135](/filings/0000950170-24-122598.md) | [147](/filings/0001193125-26-083554.md) | [147](/filings/0000950170-25-105195.md) | [155](/filings/0001193125-25-270317.md) | [179](/filings/0001193125-25-270317.md) | [155](/filings/0001193125-26-338717.md) | [203](/filings/0001193125-26-338717.md) | [187](/filings/0001193125-26-338717.md) | [221](/filings/0001193125-25-270317.md) | [258](/filings/0001193125-26-338717.md) | [279](/filings/0001193125-26-338717.md) | [241](/filings/0001193125-26-338717.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [27.2 d](/filings/0000950170-24-122598.md) | [1.1 d](/filings/0001193125-26-083554.md) | [9.7](/filings/0000950170-25-067198.md) | [2.7 d](/filings/0000950170-25-105195.md) | [(6.0) d](/filings/0001193125-25-270317.md) | [21.5 d](/filings/0001193125-26-083554.md) | [(20.0)](/filings/0001193125-26-209730.md) | [24.9 d](/filings/0001193125-26-338717.md) | [0.0 d](/filings/0001193125-25-270317.md) | [6.0 d](/filings/0001193125-26-083554.md) | [(6.2)](/filings/0001193125-26-209730.md) | [(4.3) d](/filings/0001193125-26-338717.md) |
| Share repurchases | $m | [32.2 d](/filings/0000950170-24-122598.md) | [14.5 d](/filings/0001193125-26-083554.md) | [9.7](/filings/0000950170-25-067198.md) | [11.4 d](/filings/0000950170-25-105195.md) | [6.1 d](/filings/0001193125-25-270317.md) | [28.7 d](/filings/0001193125-26-083554.md) | [6.7](/filings/0001193125-26-209730.md) | [32.5 d](/filings/0001193125-26-338717.md) | [0.0 d](/filings/0001193125-25-270317.md) | [9.8 d](/filings/0001193125-26-083554.md) | [17.1](/filings/0001193125-26-209730.md) | [11.4 d](/filings/0001193125-26-338717.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

Shares outstanding: 2,600,000 at 2026-06-30, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-338717.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.